Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin for hospitalized COVID-19 infection
IRCT20111224008507N3Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ivermectin + standard of care with Control + standard of care (2 arms). Primary endpoint: Daily clinical symptom assessment through day 7. Started May 2020; status: completed.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20111224008507N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20111224008507N3.